Compare Organon & Co. Common Stock (OGN) vs Vivmark Residential Common Shares of Beneficial Interest (VMRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Vivmark Residential Common Shares of Beneficial Interest — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Vivmark Residential Common Shares of Beneficial Interest trades at $61.44 (market cap $47.05B). The key difference: Vivmark Residential Common Shares of Beneficial Interest is far larger — about 13× Organon & Co. Common Stock's market cap, and Vivmark Residential Common Shares of Beneficial Interest pays the higher dividend (4.62%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vivmark Residential Common Shares of Beneficial Interest for 6 Days on average.
| OGN | VMRK | |
|---|---|---|
Market Cap | $3.61B | $47.05B |
Volume | 1,808,049 | 5,012,066 |
Sector | Health | Real Estate |
52-Week High | $13.81 | $70.15 |
52-Week Low | $5.70 | $57.98 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.03B | $56.15B |
Dividend Yield | 0.58% | 4.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
VMRK trades at $61.2, down 0.08% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $3.04B and net income of $1.05B for 2025, but recent quarterly EPS misses and a slight decline in 2026 profit margins highlight near-term challenges. Recent news includes institutional buying and a credit rating upgrade to 'A' by S&P Global Ratings on August 18, 2026.
The outlook is mixed: analyst consensus is a buy with a $71.67 price target, but technical weakness and earnings misses pose risks. Opportunities include strong profitability and institutional support, while risks involve execution post-merger and market volatility. The stock's valuation metrics suggest it is fairly priced relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Vivmark Residential Common Shares of Beneficial Interest
Vivmark Residential is a residential real estate investment trust that owns and operates apartment communities in U.S. markets. Its portfolio includes apartment homes and development projects.
Read more on VMRK →
